Lumos Diagnostics specializes in the development and distribution of advanced point-of-care diagnostic technologies that provide rapid and actionable information for healthcare professionals. Their flagship products include FebriDx®, a rapid test that differentiates between bacterial and non-bacterial infections using a fingerstick blood sample, and ViraDx™, which simultaneously tests for COVID-19, Influenza A, and Influenza B from nasal swab specimens. These tests are designed to deliver quick results—typically within 15 minutes—enabling healthcare providers to make informed decisions regarding patient management and treatment, particularly in urgent care settings.

In addition to their diagnostic products, Lumos offers comprehensive development and manufacturing services tailored to the needs of their clients. Their expertise encompasses the entire assay development process, from initial concept evaluation to clinical validation and commercial manufacturing. Lumos employs a phased approach to assay development, ensuring that each stage is meticulously managed to meet regulatory standards and market demands. Their capabilities include the design of various assay types, such as lateral flow and ELISA, and the integration of proprietary digital reader technologies, all aimed at enhancing the efficiency and accuracy of point-of-care diagnostics.

United States

Lumos Diagnostics, a California-based Full Service point-of-care diagnostic development company and previous spinoff from Australia-based Planet Innovation, and RPS Diagnostics, a Florida-based commercial diagnostic developer, manufacturer, and marketer of POC diagnostic tests, announced today that they have merged. The combined company will be called Lumos Diagnostics.

Lumos Diagnostics

Company Details